The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Diane K Reyes; Josephina A Vossen; Ihab R Kamel; Nilofer S Azad; Tamara A Wahlin; Michael S Torbenson; Michael A Choti; Jean-Francois H Geschwind (Profiled Authors: Michael Choti; Michael Torbenson; Ihab Kamel; Nilofer Azad; Jean Geschwind)
Department of Radiology, Johns Hopkins Hospital, Baltimore, MD, USA.
Cancer journal (Sudbury, Mass.) 2009;15(6):526-32.
PURPOSE: This prospective phase II pilot study evaluated safety and efficacy of transarterial chemoembolization (TACE) with drug-eluting beads (DEBs) loaded with doxorubicin in patients with unresectable hepatocellular carcinoma (HCC). METHODS: Twenty patients with unresectable HCC (75% Child's A, 95% Eastern Cooperative Oncology Group performance status 0 to 1, 60% Barcelona Clinic Liver Cancer C, tumor size 6.9 cm) underwent 34 DEB-TACE sessions. Primary endpoints were tumor response, assessed by contrast-enhanced magnetic resonance imaging at 1 month after treatment, using size (response evaluation criteria in solid tumors [RECIST]), contrast-enhancement (European Association for the Study of the Liver) and apparent diffusion coefficient values, and safety assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Secondary endpoints included feasibility, progression-free survival, and overall survival. RESULTS: DEB-TACE was successfully performed in 34 sessions and demonstrated a favorable safety profile. On initial (1 month) postprocedural magnetic resonance imaging, treated lesions had a mean decrease in size of 4% (P = 0.1129). Using RECIST, partial response was achieved in 2 patients (10%), and 18 patients (90%) had stable disease. Treated tumors demonstrated a mean decrease in contrast enhancement of 64% (P < 0.0001). By European Association for the Study of the Liver criteria, 12 patients (60%) had objective tumor response, and 8 (40%) had stable disease. No patients had progression of a treated lesion while undergoing treatment. At 6 months, the disease control rate was 95% using RECIST. Overall survival rates at 1 and 2 years were 65% and 55%, respectively; median overall survival was 26 months. DISCUSSION: DEB-TACE is safe and effective in achieving local tumor control in patients with unresectable HCC.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
David A Kooby; Vasili Egnatashvili; Swetha Srinivasan; Abbas Chamsuddin; Keith A Delman; John Kauh; Charles A Staley; Hyun S KimJournal of vascular and interventional radiology : JVIR 2010;21(2):224-30.
Riccardo Lencioni; Thierry de Baere; Marta Burrel; James G Caridi; Johannes Lammer; Katerina Malagari; Robert C G Martin; Elizabeth O'Grady; Maria Isabel Real; Thomas J Vogl; et al.Cardiovascular and interventional radiology 2012;35(5):980-5.
Y Bayraktar; F Balkanci; B Kayhan; B Uzunalimoglu; A Gokoz; Y Ozisik; A Gurakar; D H Van Thiel; D FiratHepato-gastroenterology 1996;43(9):681-7.
Appears in this Publication
Author of this Publication